Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 79900 [2015-32206]

Download as PDF 79900 Federal Register / Vol. 80, No. 246 / Wednesday, December 23, 2015 / Notices objectives, strategies, and priorities of NCHS. Matters for Discussion: The agenda will include: 1. Welcome remarks by the Director, NCHS 2. Presentation on ICD–10 3. Presentation on Health Interview Survey Content Redesign 4. Update on Office of Analysis and Epidemiology 5. Presentation on Web Survey Requests to make oral presentations should be submitted in writing to the contact person listed below. All requests must contain the name, address, telephone number, and organizational affiliation of the presenter. Written comments should not exceed five single-spaced typed pages in length and must be received by December 31, 2015. The agenda items are subject to change as priorities dictate. Contact Person For More Information: Virginia S. Cain, Ph.D., Director of Extramural Research, NCHS/CDC, 3311 Toledo Road, Room 7208, Hyattsville, Maryland 20782, telephone (301) 458– 4500, fax (301) 458–4024. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry. PLACE: Hyatt Pittsburgh Airport, 1111 Airport Boulevard, Pittsburgh, Pennsylvania 15231. STATUS: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. MATTERS FOR DISCUSSION: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘PAR 15–361, NIOSH Centers of Excellence for Total Worker Health’’. CONTACT PERSON FOR MORE INFORMATION: Nina Turner, Ph.D., Scientific Review Officer, NIOSH, CDC, 1095 Willowdale Road, Mailstop G905, Morgantown, West Virginia 26506, Telephone: (304) 285–5976. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Catherine Ramadei, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2015–32212 Filed 12–22–15; 8:45 am] BILLING CODE 4163–18–P Catherine Ramadei, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2015–32205 Filed 12–22–15; 8:45 am] BILLING CODE 4163–18–P Centers for Disease Control and Prevention DEPARTMENT OF HEALTH AND HUMAN SERVICES Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review Centers for Disease Control and Prevention tkelley on DSK3SPTVN1PROD with NOTICES Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to PAR 15–361, NIOSH Centers of Excellence for Total Worker Health. TIMES AND DATES: 8:00 a.m.–5:00 p.m., EST, March 16, 2016 (Closed). 8:00 a.m.–5:00 p.m., EST, March 17, 2016 (Closed). VerDate Sep<11>2014 18:05 Dec 22, 2015 Jkt 238001 In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcements (FOA) IP16–001, Research on the Epidemiology, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in Southeast Asia and the Western Pacific and (FOA) IP16–002, Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States. Time and Date: 10:00 a.m.–5:00 p.m., EST, February 24–25, 2016 (Closed). PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Research on the Epidemiology, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in Southeast Asia and the Western Pacific’’, IP16–001 and ‘‘Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States’’, IP16– 002. Contact Person for More Information: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718–8833. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Catherine Ramadei, Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2015–32206 Filed 12–22–15; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA) CK16–001, Emerging Infections Sentinel Networks (EISN) Research. Time and Date: 10:00 a.m.–5:00 p.m., January 28, 2016 (Closed). Place: Teleconference. E:\FR\FM\23DEN1.SGM 23DEN1

Agencies

[Federal Register Volume 80, Number 246 (Wednesday, December 23, 2015)]
[Notices]
[Page 79900]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32206]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Initial Review

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces a meeting for the initial review of 
applications in response to Funding Opportunity Announcements (FOA) 
IP16-001, Research on the Epidemiology, Vaccine Effectiveness and 
Treatment of Influenza and Other Respiratory Viruses in Southeast Asia 
and the Western Pacific and (FOA) IP16-002, Annual Estimates of 
Influenza Vaccine Effectiveness for Preventing Medically Attended 
Laboratory-Confirmed Influenza in the United States.
    Time and Date: 10:00 a.m.-5:00 p.m., EST, February 24-25, 2016 
(Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance with 
provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., 
and the determination of the Director, Management Analysis and Services 
Office, CDC, pursuant to Public Law 92-463.
    Matters for Discussion: The meeting will include the initial 
review, discussion, and evaluation of applications received in response 
to ``Research on the Epidemiology, Vaccine Effectiveness and Treatment 
of Influenza and Other Respiratory Viruses in Southeast Asia and the 
Western Pacific'', IP16-001 and ``Annual Estimates of Influenza Vaccine 
Effectiveness for Preventing Medically Attended Laboratory-Confirmed 
Influenza in the United States'', IP16-002.
    Contact Person for More Information: Gregory Anderson, M.S., 
M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE., 
Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 2015-32206 Filed 12-22-15; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.